APO Research
Talk to an analyst

APO RESEARCH · REPORT

AI in Respiratory Diseases

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global AI in Respiratory Diseases Market Analysis and Forecast 2026-2032

4 July 2026172 pages

Choose your research edition.

Industry ResearchAI in Respiratory Diseases Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal AI in Respiratory Diseases Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal AI in Respiratory Diseases Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AI in Respiratory Diseases Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal AI in Respiratory Diseases Market Analysis and Forecast 2026-2032172 pages · $4,950 USD

Market perspective

The global AI in Respiratory Diseases market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for AI in Respiratory Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for AI in Respiratory Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for AI in Respiratory Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for AI in Respiratory Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of AI in Respiratory Diseases include ArtiQ, Philips Healthcare, GE Healthcare, Siemens Healthineers, Swaasa AI, THIRONA, DeepMind Health, Verily and VIDA Diagnostics Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for AI in Respiratory Diseases, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of AI in Respiratory Diseases, also provides the revenue of main regions and countries. Of the upcoming market potential for AI in Respiratory Diseases, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the AI in Respiratory Diseases revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global AI in Respiratory Diseases market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for AI in Respiratory Diseases revenue, projected growth trends, production technology, application and end-user industry.

AI in Respiratory Diseases Segment by Company

ArtiQ

Philips Healthcare

GE Healthcare

Siemens Healthineers

Swaasa AI

THIRONA

DeepMind Health

Verily

VIDA Diagnostics Inc

Icometrix

Infervision

PneumoWave

Respiray

Dectrocel Healthcare

Zynnon

AI in Respiratory Diseases Segment by Type

Pulmonary Infection

MRI

CT Scan

AI in Respiratory Diseases Segment by Application

Hospital

Diagnostic Centers

Ambulatory Surgical Centers

Others

AI in Respiratory Diseases Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI in Respiratory Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AI in Respiratory Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI in Respiratory Diseases.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of AI in Respiratory Diseases in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of AI in Respiratory Diseases company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, AI in Respiratory Diseases revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global AI in Respiratory Diseases Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Pulmonary Infection Major Player Table 3. MRI Major Player Table 4. CT Scan Major Player Table 5. Global AI in Respiratory Diseases Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Diagnostic Centers Major Player Table 8. Ambulatory Surgical Centers Major Player Table 9. Others Major Player Table 10. AI in Respiratory Diseases Industry Trends Table 11. AI in Respiratory Diseases Industry Drivers Table 12. AI in Respiratory Diseases Industry Opportunities and Challenges Table 13. AI in Respiratory Diseases Industry Restraints Table 14. Global AI in Respiratory Diseases Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global AI in Respiratory Diseases Market Size by Region (2021-2026) & (US$ Million) Table 16. Global AI in Respiratory Diseases Market Share by Region (2021-2026) Table 17. Global AI in Respiratory Diseases Market Size by Region (2027-2032) & (US$ Million) Table 18. Global AI in Respiratory Diseases Market Share by Region (2027-2032) Table 19. Global AI in Respiratory Diseases Revenue by Players (US$ Million) & (2021-2026) Table 20. Global AI in Respiratory Diseases Revenue Market Share by Players (2021-2026) Table 21. Global AI in Respiratory Diseases Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global AI in Respiratory Diseases Key Players Headquarters & Area Served Table 23. Global AI in Respiratory Diseases Players, Product Type & Application Table 24. Global AI in Respiratory Diseases Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global AI in Respiratory Diseases by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global AI in Respiratory Diseases Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global AI in Respiratory Diseases Revenue by Type (2021-2026) & (US$ Million) Table 29. Global AI in Respiratory Diseases Revenue by Type (2027-2032) & (US$ Million) Table 30. Global AI in Respiratory Diseases Revenue Market Share by Type (2021-2026) Table 31. Global AI in Respiratory Diseases Revenue Market Share by Type (2027-2032) Table 32. Global AI in Respiratory Diseases Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global AI in Respiratory Diseases Revenue by Application (2021-2026) & (US$ Million) Table 34. Global AI in Respiratory Diseases Revenue by Application (2027-2032) & (US$ Million) Table 35. Global AI in Respiratory Diseases Revenue Market Share by Application (2021-2026) Table 36. Global AI in Respiratory Diseases Revenue Market Share by Application (2027-2032) Table 37. ArtiQ Company Information Table 38. ArtiQ Business Overview Table 39. ArtiQ AI in Respiratory Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. ArtiQ AI in Respiratory Diseases Product Portfolio Table 41. ArtiQ Recent Development Table 42. Philips Healthcare Company Information Table 43. Philips Healthcare Business Overview Table 44. Philips Healthcare AI in Respiratory Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Philips Healthcare AI in Respiratory Diseases Product Portfolio Table 46. Philips Healthcare Recent Development Table 47. GE Healthcare Company Information Table 48. GE Healthcare Business Overview Table 49. GE Healthcare AI in Respiratory Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. GE Healthcare AI in Respiratory Diseases Product Portfolio Table 51. GE Healthcare Recent Development Table 52. Siemens Healthineers Company Information Table 53. Siemens Healthineers Business Overview Table 54. Siemens Healthineers AI in Respiratory Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Siemens Healthineers AI in Respiratory Diseases Product Portfolio Table 56. Siemens Healthineers Recent Development Table 57. Swaasa AI Company Information Table 58. Swaasa AI Business Overview Table 59. Swaasa AI AI in Respiratory Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Swaasa AI AI in Respiratory Diseases Product Portfolio Table 61. Swaasa AI Recent Development Table 62. THIRONA Company Information Table 63. THIRONA Business Overview Table 64. THIRONA AI in Respiratory Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. THIRONA AI in Respiratory Diseases Product Portfolio Table 66. THIRONA Recent Development Table 67. DeepMind Health Company Information Table 68. DeepMind Health Business Overview Table 69. DeepMind Health AI in Respiratory Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. DeepMind Health AI in Respiratory Diseases Product Portfolio Table 71. DeepMind Health Recent Development Table 72. Verily Company Information Table 73. Verily Business Overview Table 74. Verily AI in Respiratory Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Verily AI in Respiratory Diseases Product Portfolio Table 76. Verily Recent Development Table 77. VIDA Diagnostics Inc Company Information Table 78. VIDA Diagnostics Inc Business Overview Table 79. VIDA Diagnostics Inc AI in Respiratory Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. VIDA Diagnostics Inc AI in Respiratory Diseases Product Portfolio Table 81. VIDA Diagnostics Inc Recent Development Table 82. Icometrix Company Information Table 83. Icometrix Business Overview Table 84. Icometrix AI in Respiratory Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Icometrix AI in Respiratory Diseases Product Portfolio Table 86. Icometrix Recent Development Table 87. Infervision Company Information Table 88. Infervision Business Overview Table 89. Infervision AI in Respiratory Diseases Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Infervision AI in Respiratory Diseases Product Portfolio Table 91. Infervision Recent Development Table 92. PneumoWave Company Information Table 93. PneumoWave Business Overview Table 94. PneumoWave AI in Respiratory Diseases Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. PneumoWave AI in Respiratory Diseases Product Portfolio Table 96. PneumoWave Recent Development Table 97. Respiray Company Information Table 98. Respiray Business Overview Table 99. Respiray AI in Respiratory Diseases Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Respiray AI in Respiratory Diseases Product Portfolio Table 101. Respiray Recent Development Table 102. Dectrocel Healthcare Company Information Table 103. Dectrocel Healthcare Business Overview Table 104. Dectrocel Healthcare AI in Respiratory Diseases Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Dectrocel Healthcare AI in Respiratory Diseases Product Portfolio Table 106. Dectrocel Healthcare Recent Development Table 107. Zynnon Company Information Table 108. Zynnon Business Overview Table 109. Zynnon AI in Respiratory Diseases Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Zynnon AI in Respiratory Diseases Product Portfolio Table 111. Zynnon Recent Development Table 112. North America AI in Respiratory Diseases Revenue by Type (2021-2026) & (US$ Million) Table 113. North America AI in Respiratory Diseases Revenue by Type (2027-2032) & (US$ Million) Table 114. North America AI in Respiratory Diseases Revenue by Application (2021-2026) & (US$ Million) Table 115. North America AI in Respiratory Diseases Revenue by Application (2027-2032) & (US$ Million) Table 116. North America AI in Respiratory Diseases Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. North America AI in Respiratory Diseases Revenue by Country (2021-2026) & (US$ Million) Table 118. North America AI in Respiratory Diseases Revenue by Country (US$ Million) & (2027-2032) Table 119. Europe AI in Respiratory Diseases Revenue by Type (2021-2026) & (US$ Million) Table 120. Europe AI in Respiratory Diseases Revenue by Type (2027-2032) & (US$ Million) Table 121. Europe AI in Respiratory Diseases Revenue by Application (2021-2026) & (US$ Million) Table 122. Europe AI in Respiratory Diseases Revenue by Application (2027-2032) & (US$ Million) Table 123. Europe AI in Respiratory Diseases Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. Europe AI in Respiratory Diseases Revenue by Country (2021-2026) & (US$ Million) Table 125. Europe AI in Respiratory Diseases Revenue by Country (US$ Million) & (2027-2032) Table 126. China AI in Respiratory Diseases Revenue by Type (2021-2026) & (US$ Million) Table 127. China AI in Respiratory Diseases Revenue by Type (2027-2032) & (US$ Million) Table 128. China AI in Respiratory Diseases Revenue by Application (2021-2026) & (US$ Million) Table 129. China AI in Respiratory Diseases Revenue by Application (2027-2032) & (US$ Million) Table 130. Asia AI in Respiratory Diseases Revenue by Type (2021-2026) & (US$ Million) Table 131. Asia AI in Respiratory Diseases Revenue by Type (2027-2032) & (US$ Million) Table 132. Asia AI in Respiratory Diseases Revenue by Application (2021-2026) & (US$ Million) Table 133. Asia AI in Respiratory Diseases Revenue by Application (2027-2032) & (US$ Million) Table 134. Asia AI in Respiratory Diseases Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 135. Asia AI in Respiratory Diseases Revenue by Region (US$ Million) & (2021-2026) Table 136. Asia AI in Respiratory Diseases Revenue by Region (US$ Million) & (2027-2032) Table 137. SAMEA AI in Respiratory Diseases Revenue by Type (2021-2026) & (US$ Million) Table 138. SAMEA AI in Respiratory Diseases Revenue by Type (2027-2032) & (US$ Million) Table 139. SAMEA AI in Respiratory Diseases Revenue by Application (2021-2026) & (US$ Million) Table 140. SAMEA AI in Respiratory Diseases Revenue by Application (2027-2032) & (US$ Million) Table 141. SAMEA AI in Respiratory Diseases Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. SAMEA AI in Respiratory Diseases Revenue by Country (2021-2026) & (US$ Million) Table 143. SAMEA AI in Respiratory Diseases Revenue by Country (US$ Million) & (2027-2032) Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. AI in Respiratory Diseases Image Figure 2. Global AI in Respiratory Diseases Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AI in Respiratory Diseases Market Size Share 2021 VS 2025 VS 2032 Figure 4. Pulmonary Infection Image Figure 5. MRI Image Figure 6. CT Scan Image Figure 7. Global AI in Respiratory Diseases Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global AI in Respiratory Diseases Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Diagnostic Centers Image Figure 11. Ambulatory Surgical Centers Image Figure 12. Others Image Figure 13. Global AI in Respiratory Diseases Market Size (US$ Million) & (2021-2032) Figure 14. Global AI in Respiratory Diseases Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global AI in Respiratory Diseases Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global AI in Respiratory Diseases Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global AI in Respiratory Diseases Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global AI in Respiratory Diseases Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global AI in Respiratory Diseases Revenue Market Share by Type (2021-2032) Figure 21. Global AI in Respiratory Diseases Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global AI in Respiratory Diseases Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global AI in Respiratory Diseases Revenue Market Share by Application (2021-2032) Figure 24. North America AI in Respiratory Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America AI in Respiratory Diseases Revenue Share by Type (2021-2032) Figure 26. North America AI in Respiratory Diseases Revenue Share by Application (2021-2032) Figure 27. North America AI in Respiratory Diseases Revenue Share by Country (2021-2032) Figure 28. United States AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe AI in Respiratory Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe AI in Respiratory Diseases Revenue Share by Type (2021-2032) Figure 33. Europe AI in Respiratory Diseases Revenue Share by Application (2021-2032) Figure 34. Europe AI in Respiratory Diseases Revenue Share by Country (2021-2032) Figure 35. Germany AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China AI in Respiratory Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China AI in Respiratory Diseases Revenue Share by Type (2021-2032) Figure 45. China AI in Respiratory Diseases Revenue Share by Application (2021-2032) Figure 46. Asia AI in Respiratory Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia AI in Respiratory Diseases Revenue Share by Type (2021-2032) Figure 48. Asia AI in Respiratory Diseases Revenue Share by Application (2021-2032) Figure 49. Asia AI in Respiratory Diseases Revenue Share by Region (2021-2032) Figure 50. Japan AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA AI in Respiratory Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA AI in Respiratory Diseases Revenue Share by Type (2021-2032) Figure 58. SAMEA AI in Respiratory Diseases Revenue Share by Application (2021-2032) Figure 59. SAMEA AI in Respiratory Diseases Revenue Share by Country (2021-2032) Figure 60. Brazil AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt AI in Respiratory Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Pulmonary Infection
  • MRI
  • CT Scan
Applications
  • Hospital
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Others
Companies covered
  • ArtiQ
  • Philips Healthcare
  • GE Healthcare
  • Siemens Healthineers
  • Swaasa AI
  • THIRONA
  • DeepMind Health
  • Verily
  • VIDA Diagnostics Inc
  • Icometrix
  • Infervision
  • PneumoWave
  • Respiray
  • Dectrocel Healthcare
  • Zynnon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 AI in Respiratory Diseases Market by Type
  3. 1.2.1 Global AI in Respiratory Diseases Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Pulmonary Infection
  5. 1.2.3 MRI
  6. 1.2.4 CT Scan
  7. 1.3 AI in Respiratory Diseases Market by Application
  8. 1.3.1 Global AI in Respiratory Diseases Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Diagnostic Centers
  11. 1.3.4 Ambulatory Surgical Centers
  12. 1.3.5 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 AI in Respiratory Diseases Market Dynamics
  1. 2.1 AI in Respiratory Diseases Industry Trends
  2. 2.2 AI in Respiratory Diseases Industry Drivers
  3. 2.3 AI in Respiratory Diseases Industry Opportunities and Challenges
  4. 2.4 AI in Respiratory Diseases Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global AI in Respiratory Diseases Market Perspective (2021-2032)
  2. 3.2 Global AI in Respiratory Diseases Growth Trends by Region
  3. 3.2.1 Global AI in Respiratory Diseases Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global AI in Respiratory Diseases Market Size by Region (2021-2026)
  5. 3.2.3 Global AI in Respiratory Diseases Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global AI in Respiratory Diseases Revenue by Players
  2. 4.1.1 Global AI in Respiratory Diseases Revenue by Players (2021-2026)
  3. 4.1.2 Global AI in Respiratory Diseases Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global AI in Respiratory Diseases Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global AI in Respiratory Diseases Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global AI in Respiratory Diseases Key Players Headquarters & Area Served
  7. 4.4 Global AI in Respiratory Diseases Players, Product Type & Application
  8. 4.5 Global AI in Respiratory Diseases Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global AI in Respiratory Diseases Market CR5 and HHI
  11. 4.6.3 2025 AI in Respiratory Diseases Tier 1, Tier 2, and Tier 3
5 AI in Respiratory Diseases Market Size by Type
  1. 5.1 Global AI in Respiratory Diseases Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global AI in Respiratory Diseases Revenue by Type (2021-2032)
  3. 5.3 Global AI in Respiratory Diseases Revenue Market Share by Type (2021-2032)
6 AI in Respiratory Diseases Market Size by Application
  1. 6.1 Global AI in Respiratory Diseases Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global AI in Respiratory Diseases Revenue by Application (2021-2032)
  3. 6.3 Global AI in Respiratory Diseases Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 ArtiQ
  2. 7.1.1 ArtiQ Company Information
  3. 7.1.2 ArtiQ Business Overview
  4. 7.1.3 ArtiQ AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  5. 7.1.4 ArtiQ AI in Respiratory Diseases Product Portfolio
  6. 7.1.5 ArtiQ Recent Developments
  7. 7.2 Philips Healthcare
  8. 7.2.1 Philips Healthcare Company Information
  9. 7.2.2 Philips Healthcare Business Overview
  10. 7.2.3 Philips Healthcare AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Philips Healthcare AI in Respiratory Diseases Product Portfolio
  12. 7.2.5 Philips Healthcare Recent Developments
  13. 7.3 GE Healthcare
  14. 7.3.1 GE Healthcare Company Information
  15. 7.3.2 GE Healthcare Business Overview
  16. 7.3.3 GE Healthcare AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GE Healthcare AI in Respiratory Diseases Product Portfolio
  18. 7.3.5 GE Healthcare Recent Developments
  19. 7.4 Siemens Healthineers
  20. 7.4.1 Siemens Healthineers Company Information
  21. 7.4.2 Siemens Healthineers Business Overview
  22. 7.4.3 Siemens Healthineers AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Siemens Healthineers AI in Respiratory Diseases Product Portfolio
  24. 7.4.5 Siemens Healthineers Recent Developments
  25. 7.5 Swaasa AI
  26. 7.5.1 Swaasa AI Company Information
  27. 7.5.2 Swaasa AI Business Overview
  28. 7.5.3 Swaasa AI AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Swaasa AI AI in Respiratory Diseases Product Portfolio
  30. 7.5.5 Swaasa AI Recent Developments
  31. 7.6 THIRONA
  32. 7.6.1 THIRONA Company Information
  33. 7.6.2 THIRONA Business Overview
  34. 7.6.3 THIRONA AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  35. 7.6.4 THIRONA AI in Respiratory Diseases Product Portfolio
  36. 7.6.5 THIRONA Recent Developments
  37. 7.7 DeepMind Health
  38. 7.7.1 DeepMind Health Company Information
  39. 7.7.2 DeepMind Health Business Overview
  40. 7.7.3 DeepMind Health AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  41. 7.7.4 DeepMind Health AI in Respiratory Diseases Product Portfolio
  42. 7.7.5 DeepMind Health Recent Developments
  43. 7.8 Verily
  44. 7.8.1 Verily Company Information
  45. 7.8.2 Verily Business Overview
  46. 7.8.3 Verily AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Verily AI in Respiratory Diseases Product Portfolio
  48. 7.8.5 Verily Recent Developments
  49. 7.9 VIDA Diagnostics Inc
  50. 7.9.1 VIDA Diagnostics Inc Company Information
  51. 7.9.2 VIDA Diagnostics Inc Business Overview
  52. 7.9.3 VIDA Diagnostics Inc AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  53. 7.9.4 VIDA Diagnostics Inc AI in Respiratory Diseases Product Portfolio
  54. 7.9.5 VIDA Diagnostics Inc Recent Developments
  55. 7.10 Icometrix
  56. 7.10.1 Icometrix Company Information
  57. 7.10.2 Icometrix Business Overview
  58. 7.10.3 Icometrix AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Icometrix AI in Respiratory Diseases Product Portfolio
  60. 7.10.5 Icometrix Recent Developments
  61. 7.11 Infervision
  62. 7.11.1 Infervision Company Information
  63. 7.11.2 Infervision Business Overview
  64. 7.11.3 Infervision AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Infervision AI in Respiratory Diseases Product Portfolio
  66. 7.11.5 Infervision Recent Developments
  67. 7.12 PneumoWave
  68. 7.12.1 PneumoWave Company Information
  69. 7.12.2 PneumoWave Business Overview
  70. 7.12.3 PneumoWave AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  71. 7.12.4 PneumoWave AI in Respiratory Diseases Product Portfolio
  72. 7.12.5 PneumoWave Recent Developments
  73. 7.13 Respiray
  74. 7.13.1 Respiray Company Information
  75. 7.13.2 Respiray Business Overview
  76. 7.13.3 Respiray AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Respiray AI in Respiratory Diseases Product Portfolio
  78. 7.13.5 Respiray Recent Developments
  79. 7.14 Dectrocel Healthcare
  80. 7.14.1 Dectrocel Healthcare Company Information
  81. 7.14.2 Dectrocel Healthcare Business Overview
  82. 7.14.3 Dectrocel Healthcare AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Dectrocel Healthcare AI in Respiratory Diseases Product Portfolio
  84. 7.14.5 Dectrocel Healthcare Recent Developments
  85. 7.15 Zynnon
  86. 7.15.1 Zynnon Company Information
  87. 7.15.2 Zynnon Business Overview
  88. 7.15.3 Zynnon AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Zynnon AI in Respiratory Diseases Product Portfolio
  90. 7.15.5 Zynnon Recent Developments
8 North America
  1. 8.1 North America AI in Respiratory Diseases Revenue (2021-2032)
  2. 8.2 North America AI in Respiratory Diseases Revenue by Type (2021-2032)
  3. 8.2.1 North America AI in Respiratory Diseases Revenue by Type (2021-2026)
  4. 8.2.2 North America AI in Respiratory Diseases Revenue by Type (2027-2032)
  5. 8.3 North America AI in Respiratory Diseases Revenue Share by Type (2021-2032)
  6. 8.4 North America AI in Respiratory Diseases Revenue by Application (2021-2032)
  7. 8.4.1 North America AI in Respiratory Diseases Revenue by Application (2021-2026)
  8. 8.4.2 North America AI in Respiratory Diseases Revenue by Application (2027-2032)
  9. 8.5 North America AI in Respiratory Diseases Revenue Share by Application (2021-2032)
  10. 8.6 North America AI in Respiratory Diseases Revenue by Country
  11. 8.6.1 North America AI in Respiratory Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America AI in Respiratory Diseases Revenue by Country (2021-2026)
  13. 8.6.3 North America AI in Respiratory Diseases Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe AI in Respiratory Diseases Revenue (2021-2032)
  2. 9.2 Europe AI in Respiratory Diseases Revenue by Type (2021-2032)
  3. 9.2.1 Europe AI in Respiratory Diseases Revenue by Type (2021-2026)
  4. 9.2.2 Europe AI in Respiratory Diseases Revenue by Type (2027-2032)
  5. 9.3 Europe AI in Respiratory Diseases Revenue Share by Type (2021-2032)
  6. 9.4 Europe AI in Respiratory Diseases Revenue by Application (2021-2032)
  7. 9.4.1 Europe AI in Respiratory Diseases Revenue by Application (2021-2026)
  8. 9.4.2 Europe AI in Respiratory Diseases Revenue by Application (2027-2032)
  9. 9.5 Europe AI in Respiratory Diseases Revenue Share by Application (2021-2032)
  10. 9.6 Europe AI in Respiratory Diseases Revenue by Country
  11. 9.6.1 Europe AI in Respiratory Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe AI in Respiratory Diseases Revenue by Country (2021-2026)
  13. 9.6.3 Europe AI in Respiratory Diseases Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China AI in Respiratory Diseases Revenue (2021-2032)
  2. 10.2 China AI in Respiratory Diseases Revenue by Type (2021-2032)
  3. 10.2.1 China AI in Respiratory Diseases Revenue by Type (2021-2026)
  4. 10.2.2 China AI in Respiratory Diseases Revenue by Type (2027-2032)
  5. 10.3 China AI in Respiratory Diseases Revenue Share by Type (2021-2032)
  6. 10.4 China AI in Respiratory Diseases Revenue by Application (2021-2032)
  7. 10.4.1 China AI in Respiratory Diseases Revenue by Application (2021-2026)
  8. 10.4.2 China AI in Respiratory Diseases Revenue by Application (2027-2032)
  9. 10.5 China AI in Respiratory Diseases Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia AI in Respiratory Diseases Revenue (2021-2032)
  2. 11.2 Asia AI in Respiratory Diseases Revenue by Type (2021-2032)
  3. 11.2.1 Asia AI in Respiratory Diseases Revenue by Type (2021-2026)
  4. 11.2.2 Asia AI in Respiratory Diseases Revenue by Type (2027-2032)
  5. 11.3 Asia AI in Respiratory Diseases Revenue Share by Type (2021-2032)
  6. 11.4 Asia AI in Respiratory Diseases Revenue by Application (2021-2032)
  7. 11.4.1 Asia AI in Respiratory Diseases Revenue by Application (2021-2026)
  8. 11.4.2 Asia AI in Respiratory Diseases Revenue by Application (2027-2032)
  9. 11.5 Asia AI in Respiratory Diseases Revenue Share by Application (2021-2032)
  10. 11.6 Asia AI in Respiratory Diseases Revenue by Country
  11. 11.6.1 Asia AI in Respiratory Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia AI in Respiratory Diseases Revenue by Country (2021-2026)
  13. 11.6.3 Asia AI in Respiratory Diseases Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA AI in Respiratory Diseases Revenue (2021-2032)
  2. 12.2 SAMEA AI in Respiratory Diseases Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA AI in Respiratory Diseases Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA AI in Respiratory Diseases Revenue by Type (2027-2032)
  5. 12.3 SAMEA AI in Respiratory Diseases Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA AI in Respiratory Diseases Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA AI in Respiratory Diseases Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA AI in Respiratory Diseases Revenue by Application (2027-2032)
  9. 12.5 SAMEA AI in Respiratory Diseases Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA AI in Respiratory Diseases Revenue by Country
  11. 12.6.1 SAMEA AI in Respiratory Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA AI in Respiratory Diseases Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA AI in Respiratory Diseases Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst